These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 38061213)
1. Adjuvant chemotherapy in patients with clinically node-negative but pathologically node-positive rectal cancer in the Netherlands: A retrospective analysis. Kwakman JJM; Bond MJG; Demichelis RM; Koopman M; Hompes R; Elferink MAG; Punt CJA Eur J Cancer; 2024 Jan; 197():113466. PubMed ID: 38061213 [TBL] [Abstract][Full Text] [Related]
2. Oncologic benefit of adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and curative surgery with selective lateral pelvic lymph node dissection: An international retrospective cohort study. Fukui Y; Hida K; Hoshino N; Song SH; Park SY; Choi GS; Maeda Y; Matoba S; Kuroyanagi H; Bae SU; Jeong WK; Baek SK; Sakai Y Eur J Surg Oncol; 2022 Jul; 48(7):1631-1637. PubMed ID: 35153105 [TBL] [Abstract][Full Text] [Related]
3. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial. Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Breugom AJ; van Gijn W; Muller EW; Berglund Å; van den Broek CBM; Fokstuen T; Gelderblom H; Kapiteijn E; Leer JWH; Marijnen CAM; Martijn H; Meershoek-Klein Kranenbarg E; Nagtegaal ID; Påhlman L; Punt CJA; Putter H; Roodvoets AGH; Rutten HJT; Steup WH; Glimelius B; van de Velde CJH Ann Oncol; 2015 Apr; 26(4):696-701. PubMed ID: 25480874 [TBL] [Abstract][Full Text] [Related]
5. Local recurrences in western low rectal cancer patients treated with or without lateral lymph node dissection after neoadjuvant (chemo)radiotherapy: An international multi-centre comparative study. Kroon HM; Malakorn S; Dudi-Venkata NN; Bedrikovetski S; Liu J; Kenyon-Smith T; Bednarski BK; Ogura A; van de Velde CJH; Rutten HJT; Beets GL; Thomas ML; Kusters M; Chang GJ; Sammour T Eur J Surg Oncol; 2021 Sep; 47(9):2441-2449. PubMed ID: 34120810 [TBL] [Abstract][Full Text] [Related]
6. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP; Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740 [TBL] [Abstract][Full Text] [Related]
7. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center. Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403 [TBL] [Abstract][Full Text] [Related]
8. Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer. Chen JN; Liu Z; Wang ZJ; Mei SW; Shen HY; Li J; Pei W; Wang Z; Wang XS; Yu J; Liu Q World J Gastroenterol; 2020 Jun; 26(21):2877-2888. PubMed ID: 32550762 [TBL] [Abstract][Full Text] [Related]
9. Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision. Govindarajan A; Reidy D; Weiser MR; Paty PB; Temple LK; Guillem JG; Saltz LB; Wong WD; Nash GM Ann Surg Oncol; 2011 Dec; 18(13):3666-72. PubMed ID: 21590450 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial. Zhang W; Zhou H; Jiang J; Zhu Y; Zou S; Jiang L; Tang Y; Liang J; Sun Y; Jiang Z; Qu W; Li Y; Zhou A BMC Cancer; 2023 Jun; 23(1):592. PubMed ID: 37370032 [TBL] [Abstract][Full Text] [Related]
11. ADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED RECTAL CANCER: DECIDING ON THE OPTIMAL STRATEGY. de Torres-Olombrada MV; Juez-Martel I; Rodríguez-Caravaca G; Duran-Poveda M Rev Invest Clin; 2020; 72(2):88-94. PubMed ID: 32284624 [TBL] [Abstract][Full Text] [Related]
12. The potential benefit of adjuvant chemotherapy in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy is not predicted by tumor regression grade. Bohlok A; Hendlisz A; Bouazza F; Galdon MG; Van de Stadt J; Moretti L; El Nakadi I; Liberale G Int J Colorectal Dis; 2018 Oct; 33(10):1383-1391. PubMed ID: 29984385 [TBL] [Abstract][Full Text] [Related]
13. Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated With Lateral Local Recurrence in Low Rectal Cancer After Neoadjuvant Chemoradiotherapy or Radiotherapy. Ogura A; Konishi T; Beets GL; Cunningham C; Garcia-Aguilar J; Iversen H; Toda S; Lee IK; Lee HX; Uehara K; Lee P; Putter H; van de Velde CJH; Rutten HJT; Tuynman JB; Kusters M; JAMA Surg; 2019 Sep; 154(9):e192172. PubMed ID: 31268504 [TBL] [Abstract][Full Text] [Related]
14. The effect of adjuvant chemotherapy on survival and recurrence after curative rectal cancer surgery in patients who are histologically node negative after neoadjuvant chemoradiotherapy. Baird DLH; Denost Q; Simillis C; Pellino G; Rasheed S; Kontovounisios C; Tekkis PP; Rullier E Colorectal Dis; 2017 Nov; 19(11):980-986. PubMed ID: 28493401 [TBL] [Abstract][Full Text] [Related]
15. [A single center retrospective study on surgical efficacy of T3NxM0 middle-low rectal cancer without neoadjuvant therapy]. Liu P; Lou Z; Mei Z; Gao X; Hao L; Liu L; Gong H; Meng R; Yu E; Wang H; Wang H; Zhang W Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):66-72. PubMed ID: 30703796 [TBL] [Abstract][Full Text] [Related]
16. Is adjuvant chemotherapy really needed after curative surgery for rectal cancer patients who are node-negative after neoadjuvant chemoradiotherapy? Kiran RP; Kirat HT; Burgess AN; Nisar PJ; Kalady MF; Lavery IC Ann Surg Oncol; 2012 Apr; 19(4):1206-12. PubMed ID: 21935748 [TBL] [Abstract][Full Text] [Related]
17. Treatment of clinical T1 rectal cancer in the Netherlands; a population-based overview of clinical practice. Verseveld M; Verver D; Noordman BJ; Pouwels S; Elferink MAG; de Graaf EJR; Verhoef C; Doornebosch PG; de Wilt JHW Eur J Surg Oncol; 2022 May; 48(5):1153-1160. PubMed ID: 34799230 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant Management of Pathologic Node-Positive Disease After Definitive Surgery for Clinical T1-2 N0 Rectal Cancer. Polamraju P; Haque W; Verma V; Wiederhold L; Hatch S; Butler EB; Teh BS Clin Colorectal Cancer; 2018 Sep; 17(3):e519-e530. PubMed ID: 29753642 [TBL] [Abstract][Full Text] [Related]
19. Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy. Koo T; Song C; Kim JS; Kim K; Chie EK; Kang SB; Lee KW; Kim JH; Jeong SY; Kim TY PLoS One; 2015; 10(9):e0138728. PubMed ID: 26381522 [TBL] [Abstract][Full Text] [Related]
20. Improved Survival After Adjuvant Therapy in Locally Advanced Rectal Cancer Patients With Pathologic Complete Response. Lai SH; Vogel JD; Vemuru S; Messersmith W; Lieu C; McCarter MD; Birnbaum E; Chapman BC Dis Colon Rectum; 2023 Jul; 66(7):983-993. PubMed ID: 36602514 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]